Change over period
From:
To:
Zoom:
- 3M
- 6M
- YTD
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Acumen Pharmaceuticals Inc
NASDAQ ABOS
Data sourced from
and
and
Download Data
Acumen Pharmaceuticals Inc Price to Earnings Ratio (P/E) on June 03, 2024: -14.23
Acumen Pharmaceuticals Inc Price to Earnings Ratio (P/E) is -14.23 on June 03, 2024, a -215.58% change year over year. The price to earnings ratio (P/E ratio) compares the market price per share of a company's stock to its earnings per share (EPS). It is calculated by dividing the market capitalization by the net income, divided by the number of outstanding shares. This ratio provides insights into the market's valuation of a company's earnings. A higher P/E ratio indicates that investors are willing to pay a higher price for each unit of earnings, suggesting higher market expectations for future earnings growth.
-
Acumen Pharmaceuticals Inc 52-week high Price to Earnings Ratio (P/E) is -0.01 on March 18, 2024, which is 99.92% above the current Price to Earnings Ratio (P/E).
-
Acumen Pharmaceuticals Inc 52-week low Price to Earnings Ratio (P/E) is -19.87 on May 20, 2024, which is -39.64% below the current Price to Earnings Ratio (P/E).
-
Acumen Pharmaceuticals Inc average Price to Earnings Ratio (P/E) for the last 52 weeks is -6.21.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ABOS
| CEO | Mr. Daniel J. O'Connell M.B.A. |
| IPO Date | July 1, 2021 |
| Location | United States |
| Headquarters | 427 Park Street, Charlottesville, VA, United States, 22902 |
| Employees | 51 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers. The company has a license agreement with Lonza Sales AG to manufacture and commercialize sabirnetug; and a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
Key trends
Similar companies
Day One Biopharmaceuticals Inc
NA
NA
StockViz Staff
September 19, 2024
Any question? Send us an email